209 related articles for article (PubMed ID: 9727726)
1. Safety and tolerance of zolpidem in the treatment of disturbed sleep: a post-marketing surveillance of 16944 cases.
Hajak G; Bandelow B
Int Clin Psychopharmacol; 1998 Jul; 13(4):157-67. PubMed ID: 9727726
[TBL] [Abstract][Full Text] [Related]
2. Zolpidem in insomnia: a 3-year post-marketing surveillance study in Switzerland.
Ganzoni E; Santoni JP; Chevillard V; Sébille M; Mathy B
J Int Med Res; 1995; 23(1):61-73. PubMed ID: 7774760
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy and safety of modified release zolpidem in patients with chronic insomnia].
Jiménez-Genchi A;
Rev Med Inst Mex Seguro Soc; 2012; 50(5):529-36. PubMed ID: 23282267
[TBL] [Abstract][Full Text] [Related]
4. Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial.
Fava M; Asnis GM; Shrivastava RK; Lydiard B; Bastani B; Sheehan DV; Roth T
J Clin Psychiatry; 2011 Jul; 72(7):914-28. PubMed ID: 21208597
[TBL] [Abstract][Full Text] [Related]
5. Zolpidem for insomnia.
Greenblatt DJ; Roth T
Expert Opin Pharmacother; 2012 Apr; 13(6):879-93. PubMed ID: 22424586
[TBL] [Abstract][Full Text] [Related]
6. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia.
Holm KJ; Goa KL
Drugs; 2000 Apr; 59(4):865-89. PubMed ID: 10804040
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of a polyherbal sedative-hypnotic formulation NSF-3 in primary insomnia in comparison to zolpidem: a randomized controlled trial.
Maroo N; Hazra A; Das T
Indian J Pharmacol; 2013; 45(1):34-9. PubMed ID: 23543804
[TBL] [Abstract][Full Text] [Related]
8. Continuous versus non-nightly use of zolpidem in chronic insomnia: results of a large-scale, double-blind, randomized, outpatient study.
Hajak G; Cluydts R; Declerck A; Estivill SE; Middleton A; Sonka K; Unden M
Int Clin Psychopharmacol; 2002 Jan; 17(1):9-17. PubMed ID: 11800507
[TBL] [Abstract][Full Text] [Related]
9. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia.
Scharf MB; Roth T; Vogel GW; Walsh JK
J Clin Psychiatry; 1994 May; 55(5):192-9. PubMed ID: 8071269
[TBL] [Abstract][Full Text] [Related]
10. [Safety profile of zolpidem: two studies of 3805 patients by Swiss practitioners].
Ganzoni E; Gugger M
Praxis (Bern 1994); 1999 Jun; 88(25-26):1120-7. PubMed ID: 10429550
[TBL] [Abstract][Full Text] [Related]
11. "As needed" pharmacotherapy combined with stimulus control treatment in chronic insomnia--assessment of a novel intervention strategy in a primary care setting.
Hajak G; Bandelow B; Zulley J; Pittrow D
Ann Clin Psychiatry; 2002 Mar; 14(1):1-7. PubMed ID: 12046635
[TBL] [Abstract][Full Text] [Related]
12. Multicenter, double-blind, controlled comparison of zolpidem and triazolam in elderly patients with insomnia.
Roger M; Attali P; Coquelin JP
Clin Ther; 1993; 15(1):127-36. PubMed ID: 8458042
[TBL] [Abstract][Full Text] [Related]
13. Subjective versus objective evaluation of hypnotic efficacy: experience with zolpidem.
Kryger MH; Steljes D; Pouliot Z; Neufeld H; Odynski T
Sleep; 1991 Oct; 14(5):399-407. PubMed ID: 1759092
[TBL] [Abstract][Full Text] [Related]
14. Zolpidem in the treatment of transient insomnia: a double-blind, randomized comparison with placebo.
Roth T; Roehrs T; Vogel G
Sleep; 1995 May; 18(4):246-51. PubMed ID: 7618022
[TBL] [Abstract][Full Text] [Related]
15. Eight weeks of non-nightly use of zolpidem for primary insomnia.
Walsh JK; Roth T; Randazzo A; Erman M; Jamieson A; Scharf M; Schweitzer PK; Ware JC
Sleep; 2000 Dec; 23(8):1087-96. PubMed ID: 11145323
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia.
Roth T; Soubrane C; Titeux L; Walsh JK;
Sleep Med; 2006 Aug; 7(5):397-406. PubMed ID: 16815744
[TBL] [Abstract][Full Text] [Related]
17. Controlled clinical trial of zolpidem for the treatment of insomnia associated with attention-deficit/ hyperactivity disorder in children 6 to 17 years of age.
Blumer JL; Findling RL; Shih WJ; Soubrane C; Reed MD
Pediatrics; 2009 May; 123(5):e770-6. PubMed ID: 19403468
[TBL] [Abstract][Full Text] [Related]
18. Sublingual zolpidem (Edluar™; Sublinox™).
Yang LP; Deeks ED
CNS Drugs; 2012 Nov; 26(11):1003-10. PubMed ID: 23034583
[TBL] [Abstract][Full Text] [Related]
19. Hypnotic dependence: zolpidem and zopiclone too.
Prescrire Int; 2001 Feb; 10(51):15. PubMed ID: 11503851
[TBL] [Abstract][Full Text] [Related]
20. A new sublingual formulation of zolpidem for the treatment of sleep-onset insomnia.
Staner L; Danjou P; Luthringer R
Expert Rev Neurother; 2012 Feb; 12(2):141-53. PubMed ID: 22288669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
